



2021 Alzheimer's Association International Conference (AAIC) Annual Meeting (Denver, Colorado and Virtual): Eisai Sponsored Oral Presentations and Posters

Please see the Eisai sponsored oral presentations and posters presented at the 2021 AAIC Annual Meeting listed below.

E2814

1. Schneider LS, Bateman RJ, Clifford, DB, et al. The Design of Dominantly Inherited Alzheimer's Disease Trial of the Anti-Tau Antibody, E-2814, on the DIAN-TU Tau Next Generation Platform. Virtual Oral Session presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.

E2511

1. Tomioka T, Moriyama Y, Hiramatsu N, et al. E2511, A Novel Small Compound TRKA Allosteric Modulator, Induces a Specific Trophic Signaling Via Direct Binding to TRKA, and Can Reverse the Loss of Choline Acetyl Transferase Positive Neurons in Transgenic Models of AD. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.

General Alzheimer's disease

1. Korukonda A, Dutkowski J, Ronen R, et al. Developing a Blood-Derived Biomarker Signature Specific for Alzheimer's Disease. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.
2. Miller DR, Jasuja G, Davila H, et al. Care Processes Related to Clinical Detection of Alzheimer's Disease in the US Veterans Affairs Healthcare System. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.
3. Monfared AAT, Stern Y, Doogan S, et al. Understanding the Impact of COVID-19 Pandemic on Patients with Alzheimer's Disease and Caregivers Using Online Narratives on Social Media. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.

4. Shibata K, Ariyoshi K, Azuma M, et al. Challenges of Defining Healthcare Costs for People with Mild Cognitive Impairment (MCI) Based on the Claim Database Analysis in Japan. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.

Lecanemab (BAN2401)

1. Lynch SY, Irizarry M, Dhadda S, et al. Baseline Characteristics for CLARITY-AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401) in Early Alzheimer's Disease. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.
2. Swanson CJ, Kanekiyo M, Kaplow J, et al. Plasma A β 42/40 Ratio Tracks with Changes in Brain Amyloid PET SUVR in the Core and Open-Label Extension of the Phase 2 Proof-of-Concept Study BAN2401-G000-201 Following Treatment with Lecanemab in Subjects with Early Alzheimer's Disease. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.
3. Swanson CJ, Dhadda S, Irizarry MC, et al. Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects with Early Alzheimer's Disease. Oral presentation presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.
4. Watanabe-Nakayama T, Tsuji M, Oguchi T, et al. Video Imaging of Structural Dynamics of Amyloid β Protofibrils. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.
5. Zhou J, Irizarry MC, Kramer LD, et al. AHEAD 3-45 Study: Preliminary Screening and Baseline Characteristics from a Placebo-Controlled, Double-Blind Study Evaluating Lecanemab Treatment in Participants with Preclinical Alzheimer's Disease and Elevated (A45 Trial) and Intermediate (A3 Trial) Amyloid. Oral presentation presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.

Lemborexant (E2006)

1. Pokrzywinski R, Abel C, Lenderking WR, et al. Irregular Sleep Wake Rhythm Disorder (ISWRD) Signs and Symptoms Reported Directly from Patients with Dementia and Caregivers. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 26-30, 2021; Denver, Colorado and Virtual.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the poster(s) listed above, please submit your request via www.eisaimedicalinformation.com/neurology/medicalinquiry or the Submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_medinfo@eisai.com or call 1-888-274-2378.